First liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, Guardant Health's Guardant360® CDx, advancing precision oncology in Asia, Middle East and Africa.

Donate now!

Donate now, contribute to EGR & NEXUS-IBA projects

Free consultation

If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.

We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.

First liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, Guardant Health's Guardant360® CDx, advancing precision oncology in Asia, Middle East and Africa.

SINGAPORE Aug. 7, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Guardant Health's liquid biopsy, Guardant360 CDx, for tumor mutation profiling in patients across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test.

Posted: 2020-08-07 21:29:00

Read Full Article

< Prev		Next >

EGR local time

Verse of the day

There came wise men from the east to Jerusalem, saying, Where is he that is born King of the Jews? for we have seen his star in the east, and are come to worship him. Matthew, 2. 1

Main Menu

Polls

Is wealth an indication of God’s favor or blessing?